The Ministry of Health introduced a Cancer Drug List (CDL) of clinically proven and more cost-effective cancer treatments in Sep 2022. This came after a major review of MediShield Life which found that Singapore’s expenditure on cancer drugs grew by 20 per cent annually from 2016 to 2019.
All Integrated Shield Plans (IPs) from private insurers that are purchased or renewed from Apr 1 will only cover treatments on an approved cancer drug list. How will the new policy affect patients undergoing treatment? In the long run, can this be effective in curbing the rising cost of cancer treatment?
Hear from Associate Professor Wee Hwee Lin from the NUS Saw Swee Hock School of Public Health as she weighs in.
Click here to find out more.